Zoltan Csanadi
Overview
Explore the profile of Zoltan Csanadi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
78
Citations
468
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Papp T, Kiss Z, Rokszin G, Fabian I, Mark L, Bagoly Z, et al.
Clin Ther
. 2023 Apr;
45(4):333-346.
PMID: 37028991
Purpose: Limited real-world data are available on the survival of patients treated with vitamin K antagonists (VKAs) versus with direct oral anticoagulants (DOACs) for nonvalvular atrial fibrillation (AF). In this...
12.
Raduly A, Toth A, Sarkany F, Horvath B, Szentandrassy N, Nanasi P, et al.
ESC Heart Fail
. 2023 Feb;
10(2):1326-1335.
PMID: 36722665
Aims: Heart failure with reduced ejection fraction (HFrEF) is a disease with high mortality and morbidity. Recent positive inotropic drug developments focused on cardiac myofilaments, that is, direct activators of...
13.
Raduly A, Sarkany F, Kovacs M, Bernat B, Juhasz B, Szilvassy Z, et al.
Int J Mol Sci
. 2023 Jan;
24(1).
PMID: 36613900
Recent cardiotropic drug developments have focused on cardiac myofilaments. Danicamtiv, the second direct myosin activator, has achieved encouraging results in preclinical and clinical studies, thus implicating its potential applicability in...
14.
Peter A, Balogh A, Csanadi Z, Danko K, Griger Z
Arthritis Res Ther
. 2022 Sep;
24(1):219.
PMID: 36088383
Background: Cardiac involvement in patients with idiopathic inflammatory myopathies (IIM) is associated with increased morbidity and mortality risk; however, little is known about the progression of cardiac dysfunction and long-term...
15.
Csato G, Erdei N, Vanyai B, Balla T, Czuriga D, Csanadi Z, et al.
Front Cardiovasc Med
. 2022 Aug;
9:873899.
PMID: 35935652
Aims: In-stent restenosis (ISR) is an unresolved problem following percutaneous coronary intervention (PCI), having a negative impact on clinical outcome. The main goal of this study was to find new...
16.
Illesi A, Debreceni I, Fejes Z, Nagy Jr B, Hodosi K, Kappelmayer J, et al.
Thromb Res
. 2022 Jul;
217:64-72.
PMID: 35908382
Background: Percutaneous coronary intervention (PCI) is commonly used treatment for chronic total occlusion (CTO). PCI can be performed in two different ways using wire escalation (WE) or subintimal dissection and...
17.
Urbancsek R, Csanadi Z, Forgacs I, Papp T, Boczan J, Barta J, et al.
Clin Physiol Funct Imaging
. 2022 Apr;
42(4):260-268.
PMID: 35396907
Introduction: Increased muscle sympathetic nerve activity (MSNA) indicates an adverse outcome in heart failure. Decreased baroreflex modulation of MSNA is a well-known feature of the disease. The determinability of cardiovagal...
18.
Fagyas M, Banhegyi V, Uri K, Enyedi A, Lizanecz E, Manyine I, et al.
Geroscience
. 2021 Oct;
43(5):2289-2304.
PMID: 34674152
Angiotensin-converting enzyme 2 (ACE2) is essential for SARS-CoV-2 cellular entry. Here we studied the effects of common comorbidities in severe COVID-19 on ACE2 expression. ACE2 levels (by enzyme activity and...
19.
Urbancsek R, Csanadi Z, Forgacs I, Papp T, Boczan J, Barta J, et al.
ESC Heart Fail
. 2021 Sep;
8(6):5112-5120.
PMID: 34492735
Aim: While sympathetic overactivity in heart failure (HF) with reduced ejection fraction (HFrEF; EF < 40%) is well-documented, it is ill-defined in patients with mildly reduced EF (HFmrEF; EF 40-49%)....
20.
Banhegyi V, Enyedi A, Fulop G, Olah A, Siket I, Varadi C, et al.
Cells
. 2021 Aug;
10(7).
PMID: 34359878
Inhibitors of the angiotensin converting enzyme (ACE) are the primarily chosen drugs to treat heart failure and hypertension. Moreover, an imbalance in tissue ACE/ACE2 activity is implicated in COVID-19. In...